225Ac-RAYZ-6114

N/A

Report date: 2025/11/21 17:16:38

NME

Base Information

Drug Name225Ac-RAYZ-6114

Drug Alias Name225Ac-RAYZ-6114225-Ac-RAYZ-6114

ClassificationRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionEphrin type-A receptor 2 binders

TargetsEphrin type-A receptor 2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRayzeBio Inc PeptiDream Inc

China Registration ClassN/A

Develop Information

Active CompaniesPeptiDream Inc RayzeBio Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A